Menu

Top Stories

Published on Tuesday, January 8, 2019

Shire is now part of Takeda

Shire is now part of Takeda

Takeda Pharmaceutical Company Ltd. and Shire Biotechnology company took an exciting step forward by completing the acquisition that was announced in 2018 and becoming a global biopharmaceutical company headquartered in Japan. 
 
Takeda, the largest pharmaceutical company in Asia and one of the top 10 largest pharmaceutical companies in the world, now has an expanded geographic footprint and leading positions in Japan and the United States, with the acquisition of the global specialty biopharmaceutical company, Shire, headquartered in the United Kingdom and with an operational base in the United States. 

Takeda now has an extended reach, bringing medicines to more than 80 countries and regions worldwide. The combined company enables them to deliver highly-innovative medicines and transformative care to more people around the world than ever before. Their R&D efforts are now focused on four therapeutic areas— Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases, with some specific R&D investment also committed to Plasma-Derived Therapies and Vaccines. 

The Alpha-1 Foundation congratulates Takeda in this new venture to enable the delivery of highly-innovative medicines and transformative care to more patients around the world, including the rare disease patient community, such as those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1).

To learn more, please click here.


Print

Shire is now part of Takeda

Tuesday, January 8, 2019
Takeda Pharmaceutical Company Ltd. and Shire Biotechnology company took an exciting step forward by completing the acquisition that was announced in 2018 and becoming a global biopharmaceutical company headquartered in...
Divider

Apic Bio announces $40M financing to advance novel gene therapies for rare genetic disorders

Monday, January 7, 2019
Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, announced the completion of a $40 million Series A financing led by Morningside Venture Investments, Ltd. Existing...
Divider

FDA sends warnings after several people hospitalized with infections from stem cell shots

Friday, December 21, 2018
Twelve patients became seriously ill after receiving injections that supposedly contained stem cells from umbilical cord blood, according to the U.S. Food and Drug Administration (FDA), which issued a warning to the California company, Genetech,...
Divider

Near and far, the 2018 Virtual Walk raised the bar

Tuesday, December 18, 2018
Alphas from all over the United States joined together in November for the annual Alpha-1 Foundation Virtual Walk. For 30 days, in 36 states, friends and family supported one strong mission to find a cure. From near and far, 68 teams and 40 solo...
Divider

Giants in chest medicine: Gerard M. Turino, MD

Thursday, December 13, 2018
“My initial encounter with Gerry Turino took place in 1976, during my first year as a pathology intern at Columbia-Presbyterian Hospital. I was referred to him by a colleague, after mentioning my interest in connective tissue research. When...
Divider

Medicare Open Enrollment for 2019 coverage

Thursday, December 6, 2018
Medicare health and drug plan holders can make changes annually on costs, coverage, and which providers and pharmacies are in their networks. From October 15th, 2018, through December 7th, 2018, people with Medicare can change their health plan...
Divider

Zemaira update

Tuesday, December 4, 2018
The Alpha-1 Foundation was informed by CSL Behring that Zemaira, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1), returned to normal distribution on Monday, December 3rd, 2018. This is...
Divider

Alpha-1 Foundation announces new Director of Communications

Monday, December 3, 2018
The Alpha-1 Foundation announces the appointment of Jeanne Kushner as the new Director of Communications. Kushner leaves her position as Senior Director of Development at the Foundation where she has overseen the Development Department and...
Divider

Alpha-1 friend Lynn Lothian passes away

Monday, November 26, 2018
It is with a heavy heart that the Alpha-1 Foundation shares the passing of Lynn Martine Lothian at the age of 61. Lynn began her leadership in the Alpha-1 community in 2007, when she started leading the Maryland Alpha-1 support group. When she...
Divider

Looking beyond mortality in transplantation outcomes

Tuesday, November 20, 2018
To the Centers for Medicare and Medicaid Services (CMS), whose benchmarks are the basis for whether a program is certified as a transplant center, success means being alive one year after transplantation, regardless of the quality of life of the...
Divider

Gordon L. Snider Critical Issues Workshop to focus on the COPD National Action Plan and Alpha-1

Wednesday, November 14, 2018
The 17th Gordon L. Snider Critical Issues Workshop, titled “The Alpha-1 Foundation Approach to the COPD National Action Plan” is being held on November 15th, 2018, in New York, NY, and includes expert representation from academia,...
Divider

Escape to the Cape: Team Alpha-1 made it happen, again

Thursday, November 8, 2018
Written by Judith Vargas-Vila Every September, the scenic coast of Cape Cod, Massachusetts, is the perfect stage for the annual Escape to the Cape fundraising bike trek, a 165-mile bicycle ride from Plymouth to Provincetown. An unforgettable...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive